Poliovirus serotype 2 capsid proteins (VP1–VP4)

Poliovirus serotype 2 capsid proteins are four principal structural proteins—VP1, VP2, VP3, and VP4—that assemble into an icosahedral capsid surrounding the viral RNA genome. Each mature virion contains 60 copies of each protein. VP1 forms part of the outer shell and contains the primary receptor (CD155/PVR) binding site—the "canyon"—which is key for host cell entry. The proteins together mediate virus stability, immune evasion, and host specificity. High-resolution structural studies have allowed for the mapping of antigenic sites and footprints of neutralizing antibodies, facilitating rational drug and vaccine design. Capsid-binding drugs and neutralizing antibodies either inhibit receptor engagement or stabilize the capsid to prevent genome release, representing the main therapeutic approaches targeting these proteins[1][2][4][6][7].

Other names

Poliovirus 2 capsid proteinsPV2 capsid proteinsPoliovirus type 2 VP1Poliovirus type 2 VP2Poliovirus type 2 VP3Poliovirus type 2 VP4

Capsid-binding inhibitors: Block conformational changes required for uncoating and genome release Neutralizing antibodies: Sterically block receptor (CD155/PVR) binding or promote viral aggregation and clearance[1]